Cite

HARVARD Citation

    Hong, D. et al. (2020). First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE2-receptor E-type 4 (EP4), in patients with advanced cancers. Journal for immunotherapy of cancer. 8 (1), p. . [Online]. 
  
Back to record